FENNEC PHARMACEUTICALS INC (FENC)

CA31447P1009 - Common Stock

6.42  -0.12 (-1.83%)

After market: 6.42 0 (0%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

FENNEC PHARMACEUTICALS INC

NASDAQ:FENC (6/21/2024, 7:00:01 PM)

After market: 6.42 0 (0%)

6.42

-0.12 (-1.83%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS SubIndustry
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Chartmill High Growth Momentum
EPS Q2Q%
Sales Q2Q%
CRS
6 Month-41.42%
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap175.39M
Shares
PE71.33
Fwd PE10.69
Dividend YieldN/A
Analysts
IPO
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Growth Stock Screener

Find more growth stocks the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

FENC Daily chart

Company Profile

Fennec Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company is headquartered in Research Triangle Park, North Carolina and currently employs 36 full-time employees. The company went IPO on 2001-06-05. The firm sells its product through a field force, including regional pediatric oncology specialists and medical science liaisons who are helping to educate the medical communities and patients about cisplatin induced ototoxicity and its programs supporting patient access to PEDMARK. PEDMARK is a Food and Drug Administration (FDA) approved therapy indicates to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients with localized, non-metastatic and solid tumors. The company is a formulation of sodium thiosulfate in single-dose, ready-to-use vials for intravenous use in pediatric patients. PEDMARK is a therapeutic agent with a dosing paradigm, across two open-label, randomized Phase III clinical studies, the Clinical Oncology Group (COG) Protocol ACCL0431 and SIOPEL 6.

Company Info

FENNEC PHARMACEUTICALS INC

PO Box 13628, 68 Tw Alexander Dr

RESEARCH TRIANGLE PARK NORTH CAROLINA 27709

P: 19196364530

CEO: Rostislav Raykov

Employees: 36

Website: https://fennecpharma.com/

FENC News

News Image24 days ago - Market News VideoFennec Pharmaceuticals is Now Oversold (FENC)
News Imagea month ago - InvestorPlaceFENC Stock Earnings: Fennec Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024

FENC stock results show that Fennec Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

News Imagea month ago - Fennec Pharmaceuticals Inc.Fennec Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update

~ Achieved First Quarter 2024 Total Net Revenues of $25.4 Million, Including $18.0 Million in Licensing Revenue from Recently Announced Norgine Transaction...

News Image2 months ago - Fennec Pharmaceuticals Inc.Fennec Pharmaceuticals to Report First Quarter 2024 Financial Results on May 14, 2024

RESEARCH TRIANGLE PARK, N.C., May 07, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty...

News Image2 months ago - Market News VideoRSI Alert: Fennec Pharmaceuticals (FENC) Now Oversold
News Image2 months ago - Market News VideoFENC Makes Notable Cross Below Critical Moving Average

FENC Twits

Here you can normally see the latest stock twits on FENC, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example